Kyto Biopharma, Inc. Raises $410,000 in Non-Brokered Private Placement.TORONTO -- Kyto Biopharma Inc. ("Kyto") (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :KBPH KBPH Kilobits per Hour ) today announced completion of a non-brokered private placement of 500,000 shares at a price of $0.50 USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. per share for proceeds of $250,000 USD. The Company has also converted a debt of $160,000 USD into 320,000 common shares at the same price. The proceeds from the private placement will be used by Kyto to develop its portfolio of potential targeted biologic treatments and applied to its working capital. Kyto Biopharma, Inc. Kyto Biopharma is a development stage biopharmaceutical company that develops receptor-mediated technologies to control the uptake of vitamin B12 by non-controlled proliferative cells. Vitamin B12 regulates one of two major cellular pathways for the production of folates, the cell's primary source of carbon and the progenitor pro·gen·i·tor n. 1. A direct ancestor. 2. An originator of a line of descent. progenitor ancestor, including parent. progenitor cell stem cells. for the synthesis of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. . Kyto Biopharma has a portfolio of potential targeted biologic treatments based on (i) the delivery of cytotoxic drugs using the vitamin B12 as a vehicle, (ii) the therapeutic effect of vitamin B12 depletion by receptor-mediated "Growth Blockers" and (iii) the use of monoclonal antibodies to block the uptake of vitamin B12 by non-controlled proliferative cells. Depletion of vitamin B12 levels in abnormal rapid growth and deregulated cells, such as observed in cancer and some diseases of the immune system leads to inhibition of cellular proliferation and induction of apoptosis, or programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the . This press release includes statements which may constitute "forward-looking statements". These statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Forward-looking statements involve risks and uncertainties, including but not limited to, such risks relating to the early stage of products under development, uncertainties relating to future clinical trials, dependence on third parties, the availability of capital, and risks relating to the commercialization, if any, of Kyto Biopharma's proposed products and other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion